Valued at USD 1,098.72 million in 2024, the closed system transfer device market is projected to reach USD 1,270.56 million in 2025 and USD 4,753.71 million by 2034, growing at a CAGR of 14.1% during the forecast period 2025–2034. Polaris Market Research attributes this trajectory to rising cancer cases, technological advancements, expanding healthcare facilities, regulatory compliance, and heightened safety awareness. Key players include B. Braun Medical Inc., Baxter, BD, Caragen Ltd., Cormed, Epic Medical, EQUASHIELD, ICU Medical, JMS North America Corporation, Practivet, Inc., Simplivia, Terumo Corporation, Vygon, West Pharmaceutical Services, Inc., and YUKON MEDICAL.

Oncology Centers Anchor End-User Growth

The market is segmented by end user into hospitals, ambulatory surgical centers, oncology centers & clinics, academic and research institutes, and others. Polaris expects oncology centers & clinics to witness the highest growth during the forecast period, as these specialized facilities handle a major volume of chemotherapy drugs and see growing patient numbers.

The epidemiology supports this view. The World Health Organization reported an estimated 20 million new cancer cases and 9.7 million cancer-related deaths in 2022, with 53.5 million people alive five years after diagnosis and predictions of over 35 million new cases by 2050, a 77% increase from 2022. In the United States, the American Cancer Society estimated approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in 2022. These rising cancer cases heighten the need for CSTDs that prevent leaks and contamination, protecting both patients and healthcare workers.

Technology, Component, and Closing Mechanism Segmentation

Beyond type and end user, the closed system transfer device market is segmented along several engineering dimensions. By technology, it covers air cleaning/filtration devices, diaphragm-based devices, and compartmentalized devices. By component, it spans vial access components, male luers, bag spikes, female components, and other components.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/closed-system-drug-transfer-device-market

The closing mechanism segmentation includes the click-to-lock system, luer lock system, push-to-turn system, and color-to-color alignment system. Distribution is divided between distributors and direct sales. Polaris provides revenue outlooks in USD million for each segment across 2020–2034, giving procurement and product teams a structured view of how diaphragm-based devices, vial access components, and the click-to-lock system fit within the broader landscape.

Regional Insights: North America Leads, Asia Pacific Accelerates

North America accounted for the largest share in 2024 due to high healthcare standards and a large number of healthcare facilities, alongside growing drug-safety awareness and regulatory compliance. The US closed system transfer device market held the largest share in 2024, reflecting a high incidence of disease and a correspondingly high volume of hazardous drug treatments. As an example, Baxter announced the US launch of ZOSYN (piperacillin and tazobactam) Injection in April 2023, a product associated with stringent drug safety protocols.

Asia Pacific is expected to grow at the highest CAGR from 2025 to 2034, driven by rising cancer cases and the resulting demand for chemotherapy and other drug treatments. Polaris cites a projected 1,392,179 cancer patients in India for 2020, and notes that India held the largest share in 2024, linked to the urgency and scale of vaccine rollout. In February 2022, Zydus Cadila delivered the first consignment of its COVID-19 vaccine, ZyCoV-D, to the Indian government. The report also covers Europe, Latin America, and the Middle East & Africa.

Competitive Strategy and Industry Developments

Major vendors are focusing on needle-free systems, automated transfer solutions, and advanced safety features, while prioritizing regulatory adherence. Closed System Transfer Device   Strategic partnerships, including joint ventures, product development, acquisitions, and co-marketing efforts, broaden market reach. In December 2021, B. Braun Medical Inc. introduced the OnGuard 2 CSTD in the United States, and in March 2024, Simplivia launched its SmartCompounders chemo automation solution with the Chemfort CSTD. In December 2024, NIOSH expanded its List of Hazardous Drugs, prompting hospitals to reevaluate device-compatibility matrices.

Outlook for Stakeholders

The elevated cost of CSTDs remains a restraint, particularly in lower-resource settings. Nevertheless, demand from oncology centers & clinics, continuing innovation, and regional expansion keep the closed system transfer device market on a strong path through 2034.

More Trending Latest Reports By Polaris Market Research:

fintech-market

catalyst-market

ashwagandha-extract-market

olive-oil-market

vitamin-k2-market

acrylonitrile-butadiene-styrene-abs-market

reverse-osmosis-membrane-market

supply-chain-management-market

predictive-disease-analytics-market